[转移性肾细胞癌的减瘤性肾切除术] - Suppr

Suppr

超能文献

[Cytoreductive nephrectomy in metastatic renal cell carcinoma].

作者信息

Mattigk Angelika, Zengerling Friedemann

机构信息

Klinik für Urologie und Kinderurologie, Universitätsklinikum Ulm, Ulm, Deutschland.

UroEvidence, Deutsche Gesellschaft für Urologie, Berlin, Deutschland.

出版信息

Urologie. 2024 Nov;63(11):1151-1154. doi: 10.1007/s00120-024-02461-w. Epub 2024 Nov 4.

DOI:10.1007/s00120-024-02461-w

PMID:39496942

Abstract

摘要

相似文献

[Cytoreductive nephrectomy in metastatic renal cell carcinoma].[转移性肾细胞癌的减瘤性肾切除术]

Urologie. 2024 Nov;63(11):1151-1154. doi: 10.1007/s00120-024-02461-w. Epub 2024 Nov 4.

Cytoreductive Nephrectomy Following Immunotherapy-Base Treatment in Metastatic Renal Cell Carcinoma: A Case Series and Review of Current Literature.免疫治疗基础治疗后行细胞减积性肾切除术治疗转移性肾细胞癌：病例系列及文献复习。

Curr Oncol. 2021 May 20;28(3):1921-1926. doi: 10.3390/curroncol28030178.

Impact of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma receiving systemic tyrosine kinase inhibitor therapy: A multicenter retrospective study.原发转移性肾细胞癌患者接受系统酪氨酸激酶抑制剂治疗中细胞减灭性肾切除术的影响：一项多中心回顾性研究。

Int J Urol. 2021 Apr;28(4):369-375. doi: 10.1111/iju.14466. Epub 2020 Dec 12.

Cytoreductive nephrectomy in metastatic renal cell carcinoma.转移性肾细胞癌的减瘤性肾切除术

Curr Opin Urol. 2008 Sep;18(5):474-80. doi: 10.1097/MOU.0b013e32830a4f21.

Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma.初始细胞减灭性肾切除术与初始靶向治疗转移性肾细胞癌的生存比较。

J Urol. 2018 Sep;200(3):528-534. doi: 10.1016/j.juro.2018.03.077. Epub 2018 Mar 21.

Cytoreductive nephrectomy for metastatic renal cell carcinoma, the ultimate urologic 'Choosing Wisely' campaign: a narrative review.转移性肾细胞癌的减瘤性肾切除术，泌尿外科最终的“明智选择”运动：一篇叙述性综述

Transl Cancer Res. 2020 Nov;9(11):7337-7349. doi: 10.21037/tcr-20-2343.

Therapeutic role of deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab.在接受纳武单抗联合伊匹单抗治疗的转移性肾细胞癌患者中，延迟性减瘤性肾切除术的治疗作用

Jpn J Clin Oncol. 2022 Oct 6;52(10):1208-1214. doi: 10.1093/jjco/hyac099.

Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-Trial.多中心随机对照试验：在接受检查点抑制剂治疗的同步转移性肾细胞癌中延迟细胞减灭性肾切除术：北欧-太阳试验。

BMC Cancer. 2024 Feb 24;24(1):260. doi: 10.1186/s12885-024-11987-3.

The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: A Case Series and Review of the Literature.去分化肾细胞癌的作用：肉瘤样肾细胞癌病例系列及文献复习

Curr Oncol. 2022 Aug 3;29(8):5475-5488. doi: 10.3390/curroncol29080433.

Outcome benefits of upfront cytoreductive nephrectomy for patients with metastatic renal cell carcinoma: An analysis of the TriNetX database. upfront 细胞减灭性肾切除术治疗转移性肾细胞癌患者的结局获益：TriNetX 数据库分析。

PLoS One. 2024 Mar 28;19(3):e0299102. doi: 10.1371/journal.pone.0299102. eCollection 2024.

本文引用的文献

Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.肾细胞癌：ESMO 诊断、治疗及随访临床实践指南

Ann Oncol. 2024 Aug;35(8):692-706. doi: 10.1016/j.annonc.2024.05.537. Epub 2024 May 22.

Impact of Prior Cytoreductive Nephrectomy on Efficacy in Patients with Synchronous Metastatic Renal Cell Carcinoma Treated with Avelumab plus Axitinib or Sunitinib: Post Hoc Analysis from the JAVELIN Renal 101 Phase 3 Trial.先前细胞减灭性肾切除术对阿维鲁单抗联合阿昔替尼或舒尼替尼治疗同步转移性肾细胞癌患者疗效的影响：来自 JAVELIN Renal 101 期 3 试验的事后分析。

Eur Urol. 2024 Jan;85(1):8-12. doi: 10.1016/j.eururo.2023.09.016. Epub 2023 Oct 16.

Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma.新诊断转移性肾细胞癌患者的延迟细胞减少性肾切除术。

Eur Urol. 2020 Oct;78(4):615-623. doi: 10.1016/j.eururo.2020.04.038. Epub 2020 Apr 30.

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma.JAVELIN肾101试验的最新疗效结果：一线阿维鲁单抗联合阿昔替尼与舒尼替尼治疗晚期肾细胞癌患者的对比

Ann Oncol. 2020 Aug;31(8):1030-1039. doi: 10.1016/j.annonc.2020.04.010. Epub 2020 Apr 25.

Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates?细胞减灭性肾切除术的个体化适应证：哪些标准定义了最佳候选者？

Eur Urol Oncol. 2019 Jul;2(4):365-378. doi: 10.1016/j.euo.2019.04.007. Epub 2019 May 18.

Epidemiology of Renal Cell Carcinoma.肾细胞癌的流行病学。

Eur Urol. 2019 Jan;75(1):74-84. doi: 10.1016/j.eururo.2018.08.036. Epub 2018 Sep 19.

Cytoreductive nephrectomy in the era of targeted therapies: a review.靶向治疗时代的减瘤性肾切除术：综述

BJU Int. 2017 Sep;120(3):320-328. doi: 10.1111/bju.13860. Epub 2017 May 2.

Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis.转移性肾癌患者的减瘤性肾切除术：一项联合分析

J Urol. 2004 Mar;171(3):1071-6. doi: 10.1097/01.ju.0000110610.61545.ae.

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.根治性肾切除术联合基于干扰素-α的免疫疗法与单纯干扰素-α治疗转移性肾细胞癌的随机对照试验

Lancet. 2001 Sep 22;358(9286):966-70. doi: 10.1016/s0140-6736(01)06103-7.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验